Lack of efficacy of recombinant human interleukin-6 in patients with advanced renal cell cancer: Results of a phase II study

European Journal of Cancer

Volumn 34, Issue 5, 1998, Pages 754-756

  Schuler, M ^a   Bruntsch, U ^b   Spath Schwalbe E ^c   Schrezenmeier, H ^d   Peschel, C ^a   Farber L ^e   Burger, K J ^a   Leiner, J ^b   Huber, C ^c   Aulitzky, W E ^d  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b KLINIKUM NÜRNBERG   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d Novartis Inc   (Germany)

^e ROBERT BOSCH HOSPITAL   (Germany)

Author keywords

Cancer; Immunotherapy; Interleukin 6; Kidney neoplasms; Therapeutics

Indexed keywords

RECOMBINANT INTERLEUKIN 6;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; HUMAN; KIDNEY CANCER; KIDNEY CARCINOMA; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; C-REACTIVE PROTEIN; CARCINOMA, RENAL CELL; FEMALE; HUMANS; INTERLEUKIN-6; KIDNEY NEOPLASMS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; TREATMENT FAILURE;

EID: 0032055560     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(97)10089-2     Document Type: Article

References (16)

1. Motzer RJ, Bander NH, Nanus DM. Renal cell carcinoma. N Engl J Med 1996, 335, 865-875.
2. Vogelzang NJ, Priest ER, Borden L. Spontaneous regression of histologically proved pulmonary métastases from renal cell carcinoma: a case report with 5-year follow-up. J Urol 1992, 148, 1247-1248.
3. Wirth MP. Immunotherapy for metastatic renal cell carcinoma. Urol Clin North Am 1993, 20, 283-295.
4. Vogelzang NJ, Lipton A, Figlin RA. Subcutaneous interleukin-2 plus interferon alfa-2a in metastatic renal cell cancer: an outpatient multicenter trial. J Clin Oncol 1993, 11, 1809-1816.
5. Minasian LM, Motzer RJ, Gluck L, Mazumdai M, Vlamis V, Krown SE. Interferon alfa-2a in advanced renal cell carcinoma: treatment results and survival in 159 patients with long-term follow-up. 3 Clin Oncol 1993, 11, 1368-1375.
6. Schuler M, Peschel G, Schneller F, et al. Immunomodulatory and hematopoietic effects of recombinant human interleukin-6 in patients with advanced renal cell cancer. J Interferon Cytokine Res 1996, 16, 903-910.
7. Späth-Schwalbe E, Schrezenmeier H, Bornstein S, Burger K, Porzsolt F, Born J. Endocrine effects of recombinant interleukin 6 in man. Neuroendocrinology 1996, 63, 237-243.
8. Stouthard JML, Goey H, Vries EGE de, et al. Recombinant human interleukin 6 in metastatic renal cell cancer: a phase II trial. Er J Cancer 1996, 73, 789-793.
9. Weber J, Yang JC, Topalian SL, et al. Phase I trial of subcutaneous interleukin-6 in patients with advanced malignancies. J Clin Oncol 1993, 11, 499-506.
10. Gameren M van, Willemse PHB, Mulder NH, et al. Effects of recombinant human interleukin-6 in cancer patients: a phase I-II study. Blood 1994, 84, 1434-1441.
11. Gordon MS, Nemunaitis J, Huffman R, et al. A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia. Blood 1995, 85, 3066-3076.
12. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood 1994, 83, 113-118.
13. Kishimoto T, Akira S, Narazaki M, Taga T. Interleukin-6 family of cytokines and gp!30. Blood 1995, 86, 1243-1254.
14. Kimura H, Ishibashi T, Uchida T, Maruyama Y, Friese P, Burstein SA. Interleukin 6 is a differentiation factor for human megakaryocytes in vitro. EurJ Immunol 1990, 20, 1927-1931.
15. Ikebuchi K, Wong GG, Clark SC, Ihle JN, Hirai Y, Ogawa M. Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors. Proc Natl Acad Sei USA 1987, 84, 9035-9039.
16. Sui X, Kohichiro K, Tanaka R, et al. Gpl30 and c-Kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells. Proc Natl Acad Sei USA 1995, 92, 2859-2863.